First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction Academic Article uri icon

Overview

MeSH Major

  • Amyloidosis
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Light Chains
  • Multiple Organ Failure
  • Plasma Cells

abstract

  • Monthly infusions of NEOD001 were safe and well tolerated. Recommended future dosing was 24 mg/kg. Organ response rates compared favorably with those reported previously for chemotherapy. A phase II expansion is ongoing. A global phase III study (NCT02312206) has been initiated. Antibody therapy targeting misfolded proteins is a potential new therapy for the management of AL amyloidosis.

publication date

  • April 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5470113

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.63.6530

PubMed ID

  • 26858336

Additional Document Info

start page

  • 1097

end page

  • 103

volume

  • 34

number

  • 10